fig2

Figure 2. OS by cisplatin eligibility with subgroup ranking. (A) Network geometry for cisplatin-eligible patients; (B) Forest plot of OS HRs vs. chemotherapy in cisplatin-eligible patients; (C) Heatmap of rank positions for OS and PFS in cisplatin-eligible and cisplatin-ineligible patients; (D) Heatmap of subgroup OS rankings within the cisplatin-eligible population (platinum drug, age, PD-L1 status, tumor location, gender, ECOG); (E) Network geometry for cisplatin-ineligible patients; (F) Forest plot of OS HRs vs. chemotherapy in cisplatin-ineligible patients. OS: Overall survival; HRs: hazard ratios; PFS: progression-free survival; PD-L1: programmed death-ligand 1; ECOG: Eastern Cooperative Oncology Group; ICI: immune checkpoint inhibitor; ICI+Chemo: immune checkpoint inhibitor plus chemotherapy; Chemo: platinum-based chemotherapy; ICI+ICI: dual immune checkpoint inhibitor therapy; ICI+ADC: immune checkpoint inhibitor plus antibody–drug conjugate; CI: confidence interval; NA: not applicable; ICI+TKI: immune checkpoint inhibitor plus tyrosine kinase inhibitor; Chemo+TKI: chemotherapy combined with tyrosine kinase inhibitors; Chemo+Chemo: chemotherapy doublets; UTUC: upper tract urothelial carcinoma; BC: bladder cancer.